BenzingaSeptember 9, 2026 at 8:15 AM NYLast Month
Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49
Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
